RNA interference therapy in AHP
Summing UP features the latest porphyria research in easy-to-understand summaries that have been reviewed and approved by the UPA's Scientific Advisory Board of porphyria experts.
RNA interference therapy in Acute Hepatic Porphryrias
Published in Blood May 2023
Original article: https://pubmed.ncbi.nlm.nih.gov/37027823/
This article provides an overview of the current state of research and knowledge about the use of givosiran for treating acute hepatic porphyria.
How givosiran works
Acute hepatic porphyrias are a group of 4 genetic disorders related to how the body makes an important molecule called heme in the liver. When one of the steps in the heme-making pathway doesn’t work properly, there is a block in the pathway, and the intermediate products of the heme pathway can build up in the body and cause damage. In acute hepatic porphyrias, it is believed that the buildup of a molecule called ALA can trigger porphyria attacks and chronic symptoms. These attacks cause severe abdominal pain and other neurological impacts.
Givosiran “turns down” the first step of the heme-making pathway using a type of molecule called siRNA. By making the first step of the heme pathway less active, there is a decreased buildup of ALA and other porphyrin precursors leading to decreased symptoms. The givosiran treatment is delivered by monthly injection subcutaneously (just below the skin). This is FDA approved for the treatment of adults with acute hepatic porphyrias. It is typically given in a health care facility but can also be given at home under the supervision of a visiting nurse.
Givosiran in clinical trials and in the real world
Givosiran was tested in several clinical trials. The clinical trials found that givosiran reduced the rate of porphyria attacks by 74% and improved patients’ quality of life. The trial reported side effects including pain at injection site, nausea, abdominal pain, and, in some patients, impact on kidney and liver function.
Based on the results from the clinical trials, givosiran has been approved in the United States and Europe. Precautions for administering givosiran include monitoring for allergic reactions, and liver and kidney function. Due to lack of data, givosiran is not recommended for people who are pregnant or breastfeeding.
Real world experience with givosiran has found:
Decrease in kidney function is common when starting treatment, but generally doesn’t continue to decrease over time. Decline in function was more pronounced in patients who already had decreased kidney function.
High liver enzymes were also common (32% of patients) when starting treatment. In France, treatment was paused if liver enzymes got too high, but in all cases liver enzymes returned to normal with continued givosiran treatment.
High levels of homocysteine, an amino acid, in blood have also been reported during treatment. Treatment with Vitamin B6 has been reported to resolve this issue.
The dose and frequency of givosiran can be personalized to each patient
Future research
The review also identified questions that require further research:
Are there long-term impacts from suppressing this pathway? Does that impact the body’s ability to process some medications, what impact could givosiran have on other medications?
Will givosiran have an impact on the long-term complications of AHP like chronic pain, kidney and liver diseases by decreasing ALA levels?
What is the connection between givosiran, AHP and homocysteine?
Is there a role for givosiran in the treatment of acute attacks?
Can givosiran be safely administered to pregnant and breast-feeding individuals?
Conclusions
At the end of 2022, there were 520 patients world-wide receiving givosiran. Givosiran is effective at reducing recurrent acute attacks and helps the chronic symptoms of AHP patients. There is still research needed to better understand the long-term effects and safety of givosiran.
Conclusion
The EPIQ questionnaire has the potential to be a useful tool to measure changes in patients’ symptoms, reactions, and quality of life in future clinical trials.
CONTENT REVIEWED BY UNITED PORPHYRIAS ASSOCIATION SCIENTIFIC ADVISORY BOARD
Check out related Summing UPs
